vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and GREENPOWER MOTOR Co INC. (GP). Click either name above to swap in a different company.
Coherus Oncology, Inc. is the larger business by last-quarter revenue ($12.7M vs $7.2M, roughly 1.8× GREENPOWER MOTOR Co INC.). GREENPOWER MOTOR Co INC. runs the higher net margin — -65.6% vs -295.3%, a 229.6% gap on every dollar of revenue. On growth, Coherus Oncology, Inc. posted the faster year-over-year revenue change (64.9% vs -11.5%).
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.
CHRS vs GP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $7.2M |
| Net Profit | $-37.6M | $-4.7M |
| Gross Margin | 68.3% | 14.6% |
| Operating Margin | -359.9% | — |
| Net Margin | -295.3% | -65.6% |
| Revenue YoY | 64.9% | -11.5% |
| Net Profit YoY | 25.7% | -2.1% |
| EPS (diluted) | $-0.34 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.7M | — | ||
| Q3 25 | $11.6M | — | ||
| Q2 25 | $10.3M | — | ||
| Q4 24 | — | $7.2M | ||
| Q3 24 | — | $5.3M | ||
| Q2 24 | $10.3M | $3.0M | ||
| Q4 23 | — | $8.2M | ||
| Q3 23 | $74.6M | $8.4M |
| Q4 25 | $-37.6M | — | ||
| Q3 25 | $-35.5M | — | ||
| Q2 25 | $297.8M | — | ||
| Q4 24 | — | $-4.7M | ||
| Q3 24 | — | $-4.7M | ||
| Q2 24 | $-12.9M | $-5.4M | ||
| Q4 23 | — | $-4.6M | ||
| Q3 23 | $-39.6M | $-4.3M |
| Q4 25 | 68.3% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 66.9% | — | ||
| Q4 24 | — | 14.6% | ||
| Q3 24 | — | 8.6% | ||
| Q2 24 | 82.4% | 7.4% | ||
| Q4 23 | — | 16.6% | ||
| Q3 23 | 56.1% | 14.6% |
| Q4 25 | -359.9% | — | ||
| Q3 25 | -383.1% | — | ||
| Q2 25 | -443.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -384.9% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -42.9% | — |
| Q4 25 | -295.3% | — | ||
| Q3 25 | -307.1% | — | ||
| Q2 25 | 2903.9% | — | ||
| Q4 24 | — | -65.6% | ||
| Q3 24 | — | -87.9% | ||
| Q2 24 | -125.5% | -179.8% | ||
| Q4 23 | — | -56.9% | ||
| Q3 23 | -53.2% | -50.4% |
| Q4 25 | $-0.34 | — | ||
| Q3 25 | $-0.31 | — | ||
| Q2 25 | $2.57 | — | ||
| Q4 24 | — | $-0.17 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | $-0.11 | $-0.21 | ||
| Q4 23 | — | $-0.19 | ||
| Q3 23 | $-0.41 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | $621.1K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $61.0M | $2.1M |
| Total Assets | $258.3M | $37.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.1M | — | ||
| Q3 25 | $191.7M | — | ||
| Q2 25 | $237.6M | — | ||
| Q4 24 | — | $621.1K | ||
| Q3 24 | — | $116.9K | ||
| Q2 24 | $159.2M | $528.3K | ||
| Q4 23 | — | $4.0M | ||
| Q3 23 | $131.1M | $2.0M |
| Q4 25 | $61.0M | — | ||
| Q3 25 | $87.8M | — | ||
| Q2 25 | $119.8M | — | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | $4.2M | ||
| Q2 24 | $-84.1M | $8.6M | ||
| Q4 23 | — | $18.1M | ||
| Q3 23 | $-133.6M | $22.3M |
| Q4 25 | $258.3M | — | ||
| Q3 25 | $516.5M | — | ||
| Q2 25 | $439.5M | — | ||
| Q4 24 | — | $37.4M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | $674.9M | $43.5M | ||
| Q4 23 | — | $50.2M | ||
| Q3 23 | $583.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | $-1.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.7M | — | ||
| Q3 25 | $-46.3M | — | ||
| Q2 25 | $-46.6M | — | ||
| Q4 24 | — | $-1.1M | ||
| Q3 24 | — | $-1.3M | ||
| Q2 24 | $59.7M | $-3.2M | ||
| Q4 23 | — | $1.4M | ||
| Q3 23 | $-54.3M | $-5.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
GP
Segment breakdown not available.
